- Technical Article Delayed release coating technology for nutritional supplements
- Interview with Managing Director “Entrepreneurship, team spirit and innovation has been the hall mark of Ideal Cures”
- Opening of Technical center Ideal Cures opens new R&D centre, application lab for film coating systems
| Article 01 |
| Article 02 |
News Item:- Thomson Reuters
News Item:- Pharmiweb
News Item:- Specialitychemicals
Ideal Cures Launches INSTACOAT E Series Film Coating Systems Having Ultra-Fast Coating Offering Economical & Ecological Benefits
Wed Nov 23, 2011 1:29pm EST
Ideal Cures Pvt. Ltd: Ideal Cures Launches INSTACOAT E Series Film Coating Systems Having Ultra-Fast Coating Offering Economical & Ecological Benefits
In continuation with its efforts to support pharmaceutical industry with the innovative products for film coating of tablets, Ideal Cures Pvt. Ltd an India based excipient manufacturing organization, introduces a new line of film coating materials under the brand Instacoat E Series. The products in E Series are a complete solution to the customer’s expectations for an ideal material. The philosophy behind E Series is Economic and Ecological (environmental and user friendly).
New e-series is a range of high performance coating products developed under Instacoat brand and consist of four coating systems.
| Instacoat EHP 250 | High Performance Aqueous Film coating System |
| Instacoat EMB | Efficient Moisture Barrier Aqueous Film Coating System |
| Instacoat EEN | Optimized Weight Gain Hydro-alcoholic Enteric Film Coating System |
| Instacoat EHA | High Adhesion Aqueous Film Coating System |
This will be launched in the coming CPhI Mumbai (Nov’ 30 – Dec’ 2, 2011), at Booth G28, expert team of scientists will discuss product benefits. INSTACOAT EHP 250 is a single polymer (PVA- Poly-Vinyl Alcohol) based fully aqueous coating system. The best advantage offered by the material is that the coating can be completed in less than 50% of the time, currently required with best of the materials available in the market. The product will be moderately priced, which will be suited to practically all the drug substances. The energy and time requirements are going to be reduced to very low due to fast drying of the material and the process-ability at a very high concentration and faster spray rates. The moisture barrier offered by the film coating is going to be much superior, which should help people to review the packaging components for coat savings.
Other products in the E Series spectrum are EMB, EEN and EHA. EMB is specifically developed for exclusive moisture barrier properties for highly moisture sensitive drugs, as an aqueous and fast coating system. EEN is optimized enteric coating achieved with minimum weight gain for the enteric or delayed release products. EHA is a high adhesion, immediate release HPMC based film coating system. Therefore, disintegration time and dissolution rates of the tablets products are not affected with film coatings using EHP 250 and EMB. Upon experimentation, it was noted that disintegration of the EHP and EMB film coated tablet is not affected even at a coating weight gain upto 4%.
| Process Parameters for a trial lot of 2 kg tablets in a 12” conventional pan | EHP 250 Aqueous | PVA Based Aqueous | HPMC Based Aqueous |
HPMC Based Organic Solvent |
| Reconstitution percentage (% w/w) | 25 | 20 | 11 | 5 |
| Spray Rate (g/min.) | 4 | 4 | 4 | 10 |
| Wt. of coating | ||||
| dispersion sprayed (g) | 200 | 250 | 455 | 1000 |
| Total spray time | ||||
| (mins.) | 50 | 63 | 115 | 100 |
| Proposed weight gain | 2 – 2.5% | 2 – 2.5% | 2 – 2.5% | 2 – 2.5% |
| (% w/w) | ||||
| Inlet and Bed Temp. (deg. C) |
60-70; 40-42 | 60-70; 40-42 | 60-70; 38-42 | 55-60; 35-40 |
| Pan Speed (rpm) | 18 - 20 | 18 - 20 | 18 - 20 | 18 - 20 |
| Air Pressure (kg/cm2) | 2 - 3 | 2 - 3 | 2 - 3 | 2.5 – 3.5 |
| Time Saved (%) | -- | 20% | 57% | 50% |
Speaking on the pre-launch occasion at a gathering Mr. Suresh Pareek, Managing Director said that, “This 4th generation film coating system will define the new standards of film coating systems. While others have been stumbling to develop and copy the 3rd generation coating system, we are launching Instacoat E Series. It definitely moves the bar ahead for the competition and will likely cause them to go back to the labs yet again.”
Ideal Cures is confident of the wider acceptability of these products, where scientifically it has been evaluated that the products are going to have an improved stability, longer shelf life and significant savings coupled with productivity.
Ideal Cures is an Indian company with international presence in more than 40 countries having it’s subsidiary company Ideal Cures Europe SRL, Europe and has three cGMP manufacturing plants along with modern R&D facilities at Mumbai, Vasai (India) and Milan (Italy). Ideal Cures has spent a decade in its relentless pursuit of excellence in finding tailor-made excipients and coating solutions for solid dosage forms. From ready to use Film Coating Systems, Modified release Technologies, NDDS and Acrylic Pharma Polymers to Extended Cooling Boosters and Neutral Spheres.
The product portfolio comprises INSTACOAT ready-to-use film coating systems, INSTANUTE coating technology for nutraceuticals and dietary supplements, ECOPOL range of Pharma Acrylic Polymer’s, ECOCOOL brand of cooling compounds, ESPHERES range of sugar, MCC, silicon & calcium carbonate spheres.
Ideal Cures Pvt. Ltd
Customer Relations at Ideal Cures Pvt. Ltd.
+91 22 42688700
info@idealcures.co.in
or
www.idealcures.co.in
Disclaimer:
We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers.
This also applies in respect to any rights of third parties. Our information and advice do not relieve our customer of their own responsibility for checking the suitability of our products for the envisaged purpose.
None of the products will be supplied to countries in which it could be in conflict with existing patents. However the final responsibility lies exclusively with the Buyer.